We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Skip to main content
SpringerLink
Log in

Pharmacological agents can ameliorate some of the neuropsychiatric adverse effects of interferon-α treatment

  • Drug Reactions and Interactions
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

Reference

  1. Raison CL, Demetrashvili M, Capuron L, et al. Neuropsychiatric adverse effects of interferon-α. CNS Drugs 2005; 19(2): 105–23

    Article  PubMed  CAS  Google Scholar 

  2. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358(9286): 958–65

    Article  PubMed  CAS  Google Scholar 

  3. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347(13): 975–82

    Article  PubMed  CAS  Google Scholar 

  4. Kraus MR, Schäfer A, Csef H, et al. Psychiatric side effects of pegylated interferon alfa-2b as compared to conventional interferon alfa-2b in patients with chronic hepatitis C. World J Gastroenterol 2005; 11(12): 1769–74

    PubMed  CAS  Google Scholar 

  5. Meyers CA, Scheibel RS, Forman AD. Persistent neurotoxicity of systemically administered interferon-α. Neurology 1991; 41(5): 672–6

    Article  PubMed  CAS  Google Scholar 

  6. Hoffman RG, Cohen MA, Alfonso CA, et al. Treatment of interferon-induced psychosis in patients with comorbid hepatitis C and HIV. Psychosomatics 2003; 44(5): 417–20

    Article  PubMed  Google Scholar 

  7. Musselman DL, Lawson DH, Gumnick JF, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001; 344(13): 961–6

    Article  PubMed  CAS  Google Scholar 

  8. Schaefer M, Schwaiger M, Berg T. Citalopram for the prevention of interferon-α associated depression in psychiatric risk patients. Hepatology 2003; 38(4 Suppl. 1): 320A

    Article  Google Scholar 

  9. British national formulary [online]. Available from URL: http://www.bnf.org [Accessed 2005 Jun 03]

  10. Capuron L, Gumnick JF, Musselman DL, et al. Neurobehavioral effects of interferon-α in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neurop-sychopharmacology 2002; 26(5): 643–52

    Article  CAS  Google Scholar 

  11. Schwartz AL, Thompson JA, Masood N. Interferon-induced fatigue in patients with melanoma: a pilot study of exercise and methylphenidate. Oncol Nurs Forum Online 2002; 29(7): E85–90

    Article  Google Scholar 

  12. Afdhal NH, Goon B, Smith K, et al. Epoetin alfa (EPO) improves and maintains health-related quality of life (HRQL) in anemic HCV-infected patients receiving interferon/ribavirin (IFN/RBV): HRQL results from the proactive study. Hepatology 2003; 38(4 Suppl. 1): 302A

    Article  Google Scholar 

  13. Castera L, Constant A, Henry C, et al. Incidence, risk factors and treatment of mood disorders associated with peginterferon and ribavirin therapy in patients with chronic hepatitis C: results of a prospective study [abstract]. Hepatology 2003; 38(4 Suppl. 1): 735A

    Article  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pharmacological agents can ameliorate some of the neuropsychiatric adverse effects of interferon-α treatment. Drugs Ther. Perspect 21, 18–22 (2005). https://doi.org/10.2165/00042310-200521110-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200521110-00007

Search

Navigation